Related Experiment Videos
Hepatitis C: progress and problems
1Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas 75235-8887.
Insights
Hepatitis C virus (HCV) causes liver disease, often becoming chronic. While alpha interferon offers limited treatment, preventing HCV infection is difficult due to viral mutations.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) is a primary cause of posttransfusion hepatitis.
- HCV exhibits significant genetic variability, particularly in hypervariable regions, potentially driven by immune selection.
- Diagnosis in immunocompetent individuals typically relies on serology, while immunosuppressed patients may require RNA amplification.
Purpose of the Study:
- To review the characteristics of hepatitis C virus infection.
- To discuss transmission routes, clinical manifestations, and disease progression.
- To examine current therapeutic options and challenges in prevention.
Main Methods:
- Review of existing literature on HCV virology, epidemiology, and clinical outcomes.
- Analysis of diagnostic approaches for immunocompetent and immunosuppressed populations.
- Evaluation of treatment efficacy and vaccination challenges.
Main Results:
- HCV infection frequently leads to chronic carriage with variable hepatocyte damage, fibrosis, cirrhosis, and hepatocellular carcinoma.
- Disease progression rates vary significantly among individuals.
- Alpha interferon is the sole available therapy, offering sustained remission in some but with unproven long-term benefits.
Conclusions:
- HCV infection poses a significant public health challenge due to its chronic nature and variable outcomes.
- Effective long-term treatments and preventative strategies, including vaccination, are lacking.
- Understanding the determinants of disease progression is crucial for improving patient management.
Abstract:
The hepatitis C virus (HCV), a single-stranded RNA virus, is the major cause of posttransfusion hepatitis. HCV isolates differ in nucleotide and amino acid sequences. Nucleotide changes are concentrated in hypervariable regions and may be related to immune selection. In most immunocompetent persons, HCV infection is diagnosed serologically, using antigens from conserved regions. Amplification of RNA may be necessary to detect infection in immunosuppressed patients. Transmission by known parenteral routes is frequent; other means of spread are less common and may represent inapparent, percutaneous dissemination. Infection can lead to classical acute hepatitis, but most infected persons have no history of acute disease. Once infected, most individuals apparently remain carriers of the virus, with varying degrees of hepatocyte damage and fibrosis ensuing. Chronic hepatitis may lead to cirrhosis and hepatocellular carcinoma. However, disease progression varies widely, from less than 2 years to cirrhosis in some patients to more than 30 years with only chronic hepatitis in others. Determinants important in deciding outcome are unknown. Alpha interferon, which results in sustained remission in selected patients, is the only available therapy. Long-term benefits from such therapy have not been demonstrated. Prevention of HCV infection by vaccination is likely to be challenging if ongoing viral mutation results in escape from neutralization and clearance.